Showing results (111-120 of 121) with videos related to
Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket studyShengxiang Ren, Anwen Xiong, Jia Yu, et al.Medcomm|March 12, 2024
A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancerShiwen Huo, Jinqi Xue, Shuo Wang, et al.Nature Communications|November 5, 2024
Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II studyHairong Xu, Yong Zhou, Li Liang, et al.Nature Communications|July 2, 2025
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trialNan Niu, Jinqi Xue, Guanglei Chen, et al.Cancer Cell|October 24, 2025
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 studyJia Zhong, Lin Wu, Zhengbo Song, et al.Signal Transduction and Targeted Therapy|October 8, 2025
CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patientsHaifeng Lin, Yi Han, Lei Guo, et al.Signal Transduction and Targeted Therapy|March 20, 2026
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trialHerui Yao, Min Yan, Zhongsheng Tong, et al.Nature Communications|November 17, 2022
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancerNan Niu, Fang Qiu, Qianshi Xu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I TrialHerui Yao, Min Yan, Zhongsheng Tong, et al.Signal Transduction and Targeted Therapy|February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trialDan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.Pageof 13